Updating results

737 results

Sort: Relevance | Date

Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

Proposed [GID-TA10560] Expected publication date: TBC

Technology appraisal guidance Proposed

Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

Proposed [GID-TA10562] Expected publication date: TBC

Technology appraisal guidance Proposed

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Proposed [GID-TA10563] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Primary hyperparathyroidism

Proposed [GID-QS10089] Expected publication date: TBC

Quality standard Proposed

Sleep disordered breathing

Proposed [GID-QS10096] Expected publication date: TBC

Quality standard Proposed

Managing symptoms with an uncertain cause

Proposed [GID-QS10103] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Secondary care management of malignant hypertension

Proposed [GID-QS10107] Expected publication date: TBC

Quality standard Proposed

Prevention of dementia

Proposed [GID-QS10109] Expected publication date: TBC

Quality standard Proposed

Road safety

Proposed [GID-QS10111] Expected publication date: TBC

Quality standard Proposed

Spatial planning

Proposed [GID-QS10112] Expected publication date: TBC

Quality standard Proposed

Mental well-being: life course, settings and subgroups

Proposed [GID-QS10118] Expected publication date: TBC

Quality standard Proposed

Heat wave planning

Proposed [GID-QS10116] Expected publication date: TBC

Quality standard Proposed

Non-antibiotic clinical management of infectious diseases

Proposed [GID-QS10120] Expected publication date: TBC

Quality standard Proposed

Natural environments

Proposed [GID-QS10119] Expected publication date: TBC

Quality standard Proposed

Gambling

Proposed [GID-QS10099] Expected publication date: TBC

Quality standard Proposed

Programme management: effective ways to run public health programmes to generate a change in behaviour

Proposed [GID-QS10122] Expected publication date: TBC

Quality standard Proposed

Transport and health

Proposed [GID-QS10123] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed

VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Blood transfusion in neonatology

Proposed [GID-QS10098] Expected publication date: TBC

Quality standard Proposed

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostemsavir for treating multidrug resistant HIV-1 [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]

Proposed [GID-TA10594] Expected publication date: TBC

Technology appraisal guidance Proposed

Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]

Proposed [GID-TA10595] Expected publication date: TBC

Technology appraisal guidance Proposed

Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

Proposed [GID-TA10596] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

Proposed [GID-TA10597] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Technology appraisal guidance Proposed

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Proposed [GID-TA10603] Expected publication date: TBC

Technology appraisal guidance Proposed

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Proposed [GID-TA10555] Expected publication date: TBC

Technology appraisal guidance Proposed

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Obeticholic acid for treating liver fibrosis in people with steatohepatitis [1645]

Proposed [GID-TA10606] Expected publication date: TBC

Technology appraisal guidance Proposed

Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

Proposed [GID-TA10609] Expected publication date: TBC

Technology appraisal guidance Proposed

Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

Proposed [GID-TA10610] Expected publication date: TBC

Technology appraisal guidance Proposed